Obsessive-Compulsive Disorder (OCD) is more than just occasional “perfectionism” or “neatness.” It’s a chronic neuropsychiatric condition characterized by intrusive, unwanted thoughts (obsessions) and repetitive, ritualistic behaviors (compulsions) that can severely disrupt daily life. Studies show that OCD affects 2.5% to 3% of the global population at some point in their lives, and alarmingly, 40% to 60% of patients do not respond well to first-line treatments like selective serotonin reuptake inhibitors (SSRIs) or cognitive-behavioral therapy (CBT) (Liang et al., 2021). For these individuals, repetitive Transcranial Magnetic Stimulation (rTMS) has emerged as a beacon of hope—a non-invasive, safe, and increasingly evidence-backed treatment option. In this blog, we’ll dive into what research tells us about rTMS for OCD, from how it works to who might benefit most.

Understanding the Basics: What Is rTMS, and How Does It Help OCD?

rTMS is a non-invasive neurostimulation technique that uses magnetic pulses to modulate abnormal brain activity. Unlike invasive procedures, it requires no surgery or anesthesia—patients simply sit in a chair while a small device delivers targeted magnetic pulses to specific areas of the brain. For OCD, the treatment targets the cortico-striato-thalamic-cortical (CSTC) circuit, a brain network that’s been consistently linked to the development and maintenance of OCD symptoms. Research suggests that dysfunction in this circuit (e.g., overactivity in certain regions) contributes to the intrusive thoughts and compulsive behaviors that define OCD (Blom et al., 2011).

The U.S. Food and Drug Administration (FDA) has already approved rTMS for the treatment of OCD, a testament to its growing recognition as a viable therapy (Lusicic et al., 2018). But what does the latest research reveal about its effectiveness, optimal parameters, and safety?

Key Research Findings: Targets, Frequencies, and Efficacy

One of the most critical factors in rTMS success is identifying the right brain target and stimulation frequency. Over the years, researchers have tested several brain regions, with consistent results pointing to specific areas as most effective:

1. Dorsolateral Prefrontal Cortex (DLPFC)

The DLPFC is a front-runner in rTMS treatment for OCD. Meta-analyses show that low-frequency rTMS (≤1Hz) targeted at the DLPFC yields the most significant symptom improvements, with a mean difference (MD) in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)—the gold standard for measuring OCD severity—of 6.34 (Liang et al., 2021). High-frequency rTMS (≥5Hz) to the DLPFC is also effective (MD=3.75), but its impact is notably weaker than low-frequency stimulation (Liang et al., 2021). Additionally, studies suggest that right DLPFC stimulation works best for younger patients and those with non-refractory OCD (i.e., patients who haven’t failed multiple prior treatments) (Vismara et al., 2025).

2. Supplementary Motor Area (SMA)

The SMA, a region involved in motor control and repetitive behaviors, is another promising target. Low-frequency rTMS to the SMA ranks second in efficacy (MD=4.18), with its benefits linked to reducing overactivity in this region—directly addressing the compulsive, repetitive behaviors common in OCD (Liang et al., 2021). However, some studies have failed to find a significant difference between SMA-targeted rTMS and sham (placebo) stimulation, highlighting the need for further standardization (Rostami et al., 2020).

3. Orbitofrontal Cortex (OFC) and Beyond

Low-frequency rTMS to the OFC can provide short-term symptom relief, but its long-term effects are less durable, and some research shows no meaningful difference from sham stimulation (Liang et al., 2021). More recently, high-frequency deep TMS (dTMS) targeting the anterior cingulate cortex/medial prefrontal cortex (ACC/mPFC) received FDA approval, though current evidence for this target is inconsistent and requires larger, more rigorous studies (Lusicic et al., 2018).

Safety and Tolerability: A Major Advantage of rTMS

For many patients, the safety profile of rTMS is a key selling point. Unlike some psychiatric medications or invasive procedures, rTMS has no serious long-term side effects. Research across multiple studies confirms that rTMS is well-tolerated, with adverse effects comparable to those of sham stimulation (Kar et al., 2023). The most common side effects are mild and temporary: short-lived headaches, scalp discomfort at the stimulation site, or minor dizziness. Notably, high-frequency stimulation carries a slightly higher risk of side effects than low-frequency stimulation, but these are still rare and manageable (Liang et al., 2021).

Crucially, there is no evidence that rTMS causes long-term cognitive impairment or neural damage—a major concern for patients considering long-term treatment (Kar et al., 2023).

Who Is Most Likely to Benefit from rTMS?

Not all OCD patients will respond equally to rTMS. Research has identified several key predictors of treatment success:

• Age: Patients under 35 tend to have better outcomes with rTMS (Vismara et al., 2025).
• Treatment History: Non-refractory patients (those who haven’t failed multiple prior therapies) respond more favorably than refractory patients (Liang et al., 2021).
• Symptom Characteristics: Patients with less severe interference from obsessive thoughts and greater ability to resist compulsive behaviors are more likely to see improvements (Vismara et al., 2025).
• Comorbidities: Patients with a family history of psychiatric disorders or a history of suicidal ideation may have poorer responses to rTMS (Vismara et al., 2025).

Current Limitations and the Future of rTMS for OCD

While rTMS shows great promise, it’s not without limitations. Most existing studies have small sample sizes, lack long-term follow-up, or use inconsistent stimulation parameters (e.g., different frequencies, session durations, or targets)—leading to high heterogeneity in results (I²=73.5%) (Liang et al., 2021). Nine out of 12 meta-analyses on rTMS for OCD report high heterogeneity, with effect sizes ranging from Hedge’s g=0.42 to 0.79 (standardized to 0.29–0.49), indicating a moderate overall benefit (Kar et al., 2023).

The future of rTMS for OCD lies in addressing these gaps. Researchers are calling for large-scale, double-blind randomized controlled trials (RCTs) to standardize stimulation parameters. Additionally, combining rTMS with neuroimaging (e.g., fMRI) could enable “precision targeting”—tailoring treatment to each patient’s unique brain anatomy (Lusicic et al., 2018). Finally, exploring maintenance treatment plans (e.g., periodic booster sessions) will be key to extending the long-term benefits of rTMS (Rostami et al., 2020).

Final Thoughts: Is rTMS Right for You?

If you or a loved one is living with OCD and hasn’t found relief from first-line treatments, rTMS is absolutely worth discussing with a psychiatric provider. Its non-invasive nature, strong safety profile, and growing evidence base make it a compelling option for many patients. While it’s not a “cure,” it can significantly reduce symptom severity and improve quality of life—something that millions of OCD patients desperately need.

As research continues to refine rTMS protocols, we’re moving closer to a world where OCD is no longer a lifelong barrier to happiness. For now, the best next step is to consult a specialist who can assess your individual needs and determine if rTMS is part of your path to recovery.

References

1. Liang, K., Li, H., Bu, X., et al. (2021). Efficacy and tolerability of repetitive transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Translational Psychiatry, 11(1), 332. https://doi.org/10.1038/s41398-021-01453-0
2. Blom, R. M., Figee, M., Vulink, N., et al. (2011). Update on repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: different targets. Current Psychiatry Reports, 13(4), 289–294. https://doi.org/10.1007/s11920-011-0205-3
3. Lusicic, A., Schruers, K. R. J., Pallanti, S., et al. (2018). Transcranial magnetic stimulation in the treatment of obsessive–compulsive disorder: current perspectives. Neuropsychiatric Disease and Treatment, 14, 1721–1736. https://doi.org/10.2147/NDT.S121140
4. Vismara, M., Torriero, S., La Monica, K., et al. (2025). Augmentative transcranial magnetic stimulation over the left orbitofrontal cortex in patients with treatment-resistant obsessive-compulsive disorder: An acute and follow-up study. Neuroscience Applied, 4, 105511. https://doi.org/10.1016/j.nsa.2025.105511
5. Rostami, R., Kazemi, R., Jabbari, A., et al. (2020). Efficacy and clinical predictors of response to rTMS treatment in pharmacoresistant obsessive-compulsive disorder (OCD): a retrospective study. BMC Psychiatry, 20(1), 372. https://doi.org/10.1186/s12888-020-02769-9
6. Kar, S. K., Agrawal, A., Silva-dos-Santos, A., et al. (2023). The Efficacy of Transcranial Magnetic Stimulation in the Treatment of Obsessive-Compulsive Disorder: An Umbrella Review of Meta-Analyses. CNS Spectrums, 29(2), 109–118. https://doi.org/10.1017/S1092852923006387